Rheumatology Medical News about systemic lupus erythematosus; elderly

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Systemic Lupus Erythematosus in the Elderly
International Journal of Gerontology, 07/30/09

Chen T–L et al. – Late onset SLE patients had more insidious onset, a longer lag time from disease onset to diagnosis, higher rates of renal insufficiency and mortality, lower positive rates of anti–dsDNA antibody, anti–RNP antibody and hypocomplementemia, and lower female predominance than the early onset patients. The most frequent cause of death in both groups was septic shock. Thus, this particular subgroup of SLE patients should be afforded greater attention to avoid delayed diagnosis or misdiagnosis.

Methods

The authors retrospectively reviewed and analyzed 19 SLE patients with disease onset at age 60 years or older (Group A) collected from 1998 to 2008 in the computerized database of outpatients and inpatients of Mackay Memorial Hospital
For comparison, 50 SLE patients with disease onset between 15 and 40 years (Group B) were also selected using a simple random sampling method during the same period from the same database

Results

The female predominance was reduced in Group A.
The duration from disease onset to diagnosis was longer in Group A.
The incidence of renal insufficiency and mortality rate were significantly higher in Group A.
The immunologic disorder rates, anti–dsDNA antibodies, hypocomplementemia and anti–ribonucleoprotein (RNP) antibodies, however, were significantly lower in Group A.

<< Previous
Selective modulation of T-cell co-stimulation: A novel mode of...

Next >>
Denosumab for joints and bones